



## The Role of NK Cells in Hematological Malignancies

Guest Editor:

### Message from the Guest Editor

**Dr. Matthew Blunt**

School of Clinical and  
Experimental Sciences, Faculty of  
Medicine, University of  
Southampton, Southampton  
SO16 6YD, UK

Natural killer (NK) cells possess the ability to rapidly lyse tumour cells and promote the anti-cancer activity of other immune cell types, including macrophages, CD8<sup>+</sup> T cells and dendritic cells.

Deadline for manuscript  
submissions:

**30 June 2024**

Increased knowledge of the role of NK cells in hematological malignancies will provide new avenues for research and allow for improved utilization against tumour cells in the clinical setting. In this Special Issue, we invite investigators to contribute original research, as well as review articles, that address recent advances in NK cell function with regard to haematological malignancies. We welcome authors to submit manuscripts that provide novel insights on NK cell biology and therapeutic strategies including CAR-NK cells, cytokines, tumour-targeting antibodies, NK cell engagers, and checkpoint inhibitors.

Keywords: NK cells; lymphoma; multiple myeloma; CLL; AML; leukaemia; immunotherapy





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)